LAOPU GOLD Issues Positive Profit Alert, Anticipates FY2025 Net Profit of Approximately 4.8 to 4.9 Billion Yuan

Stock News03-12

Significant Corporate Announcements: Guanghe Technology (01989) initiated its public offering from March 12 to March 17, planning a global sale of 46 million H shares. Sino Biopharmaceutical (01177) announced that the clinical trial for TQB3205 (a pan-KRAS inhibitor) has received approval from the NMPA. Binhai Investment (02886) entered into a strategic cooperation framework agreement with TEDA Urban Renewal to jointly promote the national "Good Houses" initiative and enhance urban quality. Hengrui Pharmaceuticals (01276) disclosed that its SHR-2524 injection has obtained a drug clinical trial approval notice. Lepu Biopharma-B (02157) reported that AstraZeneca has paid a milestone payment of $45 million.

Operational Performance: LAOPU GOLD (06181) issued a positive profit alert, forecasting a net profit attributable for the 2025 fiscal year in the range of approximately 4.8 billion to 4.9 billion yuan, representing a year-on-year increase of about 226% to 233%. Cathay Pacific Airways (00293) released its full-year 2025 results, reporting a profit attributable to shareholders of HK$10.828 billion, up 9.51% year-on-year. Metallurgical Corporation of China (01618) reported new contract signings valued at 132.44 billion yuan for the first two months of the year, a decrease of 6.49% compared to the same period last year. Far East Horizon (03360) announced its 2025 annual results, with profit attributable to owners for the year reaching 3.889 billion yuan, a slight increase of 0.67%. Yue Yuen Industrial (00551) disclosed its 2025 financial results, showing a profit attributable to owners of the company of approximately $381 million, a decrease of 2.9% compared to the previous year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment